The right heart in patients with cancer: a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

Author(s):
Keramida, K.; Farmakis, D.; Rakisheva, A.; Tocchetti, C.G.; Ameri, P.; Asteggiano, R.; Barac, A.; Bax, J.; Bayes-Genis, A.; Klein, J.B.; Bucciarelli-Ducci, C.; Celutkiene, J.; Coats, A.J.S.; Solal, A.C.; Dent, S.; Filippatos, G.; Ghosh, A.; Hermann, J.; Koop, Y.; Lenihan, D.; Fernandez, T.L.; Lyon, A.R.; Mercurio, V.; Moura, B.; Piepoli, M.; Sener, Y.Z.; Suter, T.; Sverdlov, A.L.; Tadic, M.; Thum, T.; Meer, P. van der; Linthout, S. van; Metra, M.; Rosano, G.
Published
2024
Publication type
Article / Letter to editor

Abstract

Cardio-oncology guidelines, position statements and clinical trials have focused on the cardiotoxic effects of cancer therapies upon the left ventricle.1,2 However, cancer therapies, including chemotherapy, targeted therapies, immunotherapies and radiation therapy (RT) may also have detrimental effects on the right

heart (RH). These effects may manifest as right ventricular (RV) dysfunction, pulmonary hypertension (PH), pericardial disease and valvular abnormalities. The prevalence and clinical significance of RH involvement in patients treated with cancer therapies are being increasingly recognized,3 as these conditions can signifi-

cantly impact treatment decisions, prognosis, and overall patient outcomes.4 In this scientific statement, we aim to discuss the impact of cancer therapies on the RH and explore the importance of RH assessment in patients with cancer. We discuss the prevalence and the mechanisms of RV dysfunction in cancer patients, the challenges and limitations of traditional imaging modalities, and the role of multimodality imaging in evaluating the RH. The integration of RH assessment into cardio-oncology practice will aid healthcare

professionals to proactively manage cardiovascular (CV) complications, optimize cancer treatment strategies, and potentially improve clinical outcomes.

Right ventricleCancerCardiotoxicity
Date issued
2024-10-31
Language
English
Is part of
European Journal of Heart Failure (2024), Vol. 26, no. 10, p. 2077-2093
hdl
1887/4246682
doi
10.1002/ejhf.3412
URL
https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3412